Celltrion Pharm Inc. stock analysis
Want to see KR:068760 full AI Analyst Report?
Celltrion Pharm Inc. (068760) Stock Price & Analysis
068760 Stock Chart & Stats
- Day’s Range
- KRW 40,850.00 - KRW 42,500.00
- 52-Week Range
- KRW 35,600.00 - KRW 78,300.00
- Previous Close
- KRW 40,250.00
- Volume
- N/A
- Average Volume (3M)
- 66.54K
- Market Cap
- KRW 1.78T
- Enterprise Value
- KRW 1.85T
- Total Cash (Recent Filing)
- KRW 116.93B
- Total Debt (Recent Filing)
- KRW 161.31B
- Price to Earnings (P/E)
- 130.9
- Beta
- 0.22
- Next Earnings
- Mar 22, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Dec 29, 2025
- Dividend Yield
- 0.37%
Bulls Say, Bears Say
Bulls Say
Revenue And Profitability Growth
The strong 2025 revenue step-up, combined with improved EBIT and EBITDA margins, indicates that Celltrion Pharm is expanding its operating earnings base. A broader and more profitable revenue platform can support reinvestment, strengthen execution capacity, and provide more durable earnings potential over the next several quarters.
Improving Balance Sheet
Lower debt-to-equity and steady equity growth improve financial resilience relative to the company’s earlier position. This gives Celltrion Pharm greater flexibility to support its pharmaceutical operations and absorb earnings variation, while reducing the balance-sheet pressure associated with higher leverage.
Recent Cash Generation
Strong operating and free cash flow in the two most recent years shows that recent earnings have translated into meaningful internal cash generation. This supports ongoing investment and financial flexibility, while free cash flow covering a large portion of net income provides evidence of improved earnings quality in the near term.
Bears Say
Cash-Flow Volatility
The uneven cash-flow record makes the durability of earnings conversion less certain than the recent income statement suggests. Negative cash flow in 2022, very low free cash flow in 2023, and a 2025 decline versus 2024 could constrain internally funded investment if this volatility returns.
Margins Below Earlier Peaks
Although profitability improved in 2025, net margin remains below the company’s earlier highs, pointing to persistent mix or expense pressure. This limits the extent to which revenue growth converts into bottom-line expansion and means future earnings growth may require continued operating improvement.
Debt And Moderate Returns
Deleveraging is constructive, but the remaining absolute debt load still warrants monitoring if profitability softens. At the same time, returns are described as moderate rather than standout, suggesting that the expanded asset and equity base has not yet produced consistently strong capital efficiency.
068760 FAQ
What was Celltrion Pharm Inc.’s price range in the past 12 months?
What is Celltrion Pharm Inc.’s market cap?
When is Celltrion Pharm Inc.’s upcoming earnings report date?
How were Celltrion Pharm Inc.’s earnings last quarter?
Is Celltrion Pharm Inc. overvalued?
Does Celltrion Pharm Inc. pay dividends?
What is Celltrion Pharm Inc.’s EPS estimate?
How many shares outstanding does Celltrion Pharm Inc. have?
What happened to Celltrion Pharm Inc.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Celltrion Pharm Inc.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Celltrion Pharm Inc.
Celltrion Pharm Inc. operates within South Korea's healthcare industry, primarily focusing on the production and distribution of a diverse range of pharmaceutical products. These include heptatonics, pain relievers, fever reducers, anti-inflammatory medications, allergy treatments, medications for respiratory ailments, and antibacterial agents.
- Sector
- General
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- KR
Celltrion Pharm Inc. (068760) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 4 | 5 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 9 | 0 | 3 |

